Healthcare Stocks in Focus: 12 Stocks Moving in Monday's Pre-Market Session
PorAinvest
martes, 14 de octubre de 2025, 8:23 pm ET1 min de lectura
ACON--
ENDRA Life Sciences announced $4.9 million in funding commitments from institutional and cryptocurrency investors to launch a new digital asset treasury strategy, which could explain the significant increase in its stock price [2]. The company plans to focus on high-conviction decentralized finance holdings managed by Arca Investment Management LLC, and the deal is expected to close around October 14, 2025, pending customary conditions.
Health care stocks were generally lower late Friday afternoon, with the NYSE Health Care Index down 1.4% and the Health Care Select Sector SPDR Fund (XLV) falling 1.5% [1]. Novo Nordisk (NVO) shares were down 2.8% after winding down its cell therapy division that had been working on a potential cure for type 1 diabetes. Bristol-Myers Squibb (BMY) agreed to buy privately-held Orbital Therapeutics in an all-cash deal worth about $1.5 billion, boosting its cell therapy portfolio, but Bristol-Myers shares fell 1.6%. AstraZeneca (AZN) shares shed 1% after agreeing on a deal with President Donald Trump to lower drug prices in the US.
Financial stocks were advancing pre-bell Monday, with the Financial Select Sector SPDR Fund (XLF) 0.8% higher [3]. JPMorgan Chase (JPM) shares were up more than 1% after announcing a new $1.5 trillion, 10-year plan to facilitate, finance, and invest in industries critical to US economic security. Banco Santander (SAN) shares were up more than 2% pre-bell after being selected by the US Treasury to purchase Argentine pesos in the market as part of a broader support effort.
FORA--
NDRA--
RYOJ--
Several health care stocks are moving in Monday's pre-market session, with ENDRA Life Sciences and Aclarion leading the gains, up 45.8% and 34.34%, respectively. Forian and rYojbaba also rose, while Nanobiotix and Predictive Oncology increased by 15.84% and 15.55%, respectively. However, Tvardi Therapeutics declined by 88.0%, and other stocks like Catheter Precision, Aditxt, Quoin Pharmaceuticals, Bluejay Diagnostics, and Ensysce Biosciences fell by 15.95%, 15.92%, 12.69%, 12.23%, and 11.12%, respectively.
Several health care stocks have shown varied performance in Monday's pre-market session. ENDRA Life Sciences (NDRA) and Aclarion are leading the gains, with ENDRA up 45.8% and Aclarion up 34.34% respectively. Forian and rYojbaba also rose, while Nanobiotix and Predictive Oncology increased by 15.84% and 15.55% respectively. However, Tvardi Therapeutics declined by 88.0%, and other stocks like Catheter Precision, Aditxt, Quoin Pharmaceuticals, Bluejay Diagnostics, and Ensysce Biosciences fell by 15.95%, 15.92%, 12.69%, 12.23%, and 11.12% respectively.ENDRA Life Sciences announced $4.9 million in funding commitments from institutional and cryptocurrency investors to launch a new digital asset treasury strategy, which could explain the significant increase in its stock price [2]. The company plans to focus on high-conviction decentralized finance holdings managed by Arca Investment Management LLC, and the deal is expected to close around October 14, 2025, pending customary conditions.
Health care stocks were generally lower late Friday afternoon, with the NYSE Health Care Index down 1.4% and the Health Care Select Sector SPDR Fund (XLV) falling 1.5% [1]. Novo Nordisk (NVO) shares were down 2.8% after winding down its cell therapy division that had been working on a potential cure for type 1 diabetes. Bristol-Myers Squibb (BMY) agreed to buy privately-held Orbital Therapeutics in an all-cash deal worth about $1.5 billion, boosting its cell therapy portfolio, but Bristol-Myers shares fell 1.6%. AstraZeneca (AZN) shares shed 1% after agreeing on a deal with President Donald Trump to lower drug prices in the US.
Financial stocks were advancing pre-bell Monday, with the Financial Select Sector SPDR Fund (XLF) 0.8% higher [3]. JPMorgan Chase (JPM) shares were up more than 1% after announcing a new $1.5 trillion, 10-year plan to facilitate, finance, and invest in industries critical to US economic security. Banco Santander (SAN) shares were up more than 2% pre-bell after being selected by the US Treasury to purchase Argentine pesos in the market as part of a broader support effort.

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios